GV (Google Ventures)

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
4
Confirmed lead rounds
1
1 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$941M
4 disclosed · full round size, not this investor’s share

By stage

Series C+2
Series A1
Undisclosed1

By primary sector

Biotech4

By country

United States3
United Kingdom1

Rounds

4 in this selection
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A
Participant
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Lead
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed